104 related articles for article (PubMed ID: 16288312)
1. Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software.
Capalbo C; Ricevuto E; Vestri A; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
Eur J Hum Genet; 2006 Jan; 14(1):49-54. PubMed ID: 16288312
[TBL] [Abstract][Full Text] [Related]
2. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
4. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.
Marroni F; Aretini P; D'Andrea E; Caligo MA; Cortesi L; Viel A; Ricevuto E; Montagna M; Cipollini G; Federico M; Santarosa M; Marchetti P; Bailey-Wilson JE; Bevilacqua G; Parmigiani G; Presciuttini S
Eur J Hum Genet; 2004 Nov; 12(11):899-906. PubMed ID: 15340362
[TBL] [Abstract][Full Text] [Related]
5. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
Egeli U; Cecener G; Tunca B; Tasdelen I
Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
[TBL] [Abstract][Full Text] [Related]
6. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.
Rao NY; Hu Z; Yu JM; Li WF; Zhang B; Su FX; Wu J; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 Aug; 116(3):563-70. PubMed ID: 18807178
[TBL] [Abstract][Full Text] [Related]
8. Assessing BRCA carrier probabilities in extended families.
Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
[TBL] [Abstract][Full Text] [Related]
9. Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations.
Teller P; Hoskins KF; Zwaagstra A; Stanislaw C; Iyengar R; Green VL; Gabram SG
Ann Surg Oncol; 2010 Jan; 17(1):240-6. PubMed ID: 19763692
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families.
Gerdes AM; Cruger DG; Thomassen M; Kruse TA
Clin Genet; 2006 Feb; 69(2):171-8. PubMed ID: 16433698
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
Vogel KJ; Atchley DP; Erlichman J; Broglio KR; Ready KJ; Valero V; Amos CI; Hortobagyi GN; Lu KH; Arun B
J Clin Oncol; 2007 Oct; 25(29):4635-41. PubMed ID: 17925560
[TBL] [Abstract][Full Text] [Related]
12. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
Evans DG; Young K; Bulman M; Shenton A; Wallace A; Lalloo F
Clin Genet; 2008 Apr; 73(4):338-45. PubMed ID: 18312450
[TBL] [Abstract][Full Text] [Related]
13. Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models.
Bodmer D; Ligtenberg MJ; van der Hout AH; Gloudemans S; Ansink K; Oosterwijk JC; Hoogerbrugge N
Br J Cancer; 2006 Sep; 95(6):757-62. PubMed ID: 16909138
[TBL] [Abstract][Full Text] [Related]
14. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
[TBL] [Abstract][Full Text] [Related]
16. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
17. Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
Moghadasi S; Grundeken V; Janssen LAM; Dijkstra NH; RodrÃguez-Girondo M; van Zelst-Stams WAG; Oosterwijk JC; Ausems MGEM; Oldenburg RA; Adank MA; Blom EW; Ruijs MWG; van Os TAM; van Deurzen CHM; Martens JWM; Schroder CP; Wijnen JT; Vreeswijk MPG; van Asperen CJ
Clin Genet; 2018 Jan; 93(1):52-59. PubMed ID: 28589637
[TBL] [Abstract][Full Text] [Related]
18. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
Golshan M; Miron A; Nixon AJ; Garber JE; Cash EP; Iglehart JD; Harris JR; Wong JS
Am J Surg; 2006 Jul; 192(1):58-62. PubMed ID: 16769276
[TBL] [Abstract][Full Text] [Related]
19. Validation of three BRCA1/2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families.
Schneegans SM; Rosenberger A; Engel U; Sander M; Emons G; Shoukier M
Fam Cancer; 2012 Jun; 11(2):181-8. PubMed ID: 22160602
[TBL] [Abstract][Full Text] [Related]
20. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.
James PA; Doherty R; Harris M; Mukesh BN; Milner A; Young MA; Scott C
J Clin Oncol; 2006 Feb; 24(4):707-15. PubMed ID: 16446345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
